← United States · All US Insider Profiles
US INSIDER PROFILE · NON-SCORING RESEARCH
Kayyem Jon Faiz
Director
Identity: SEC reporting-owner CIK · Reporting-owner CIK: 0001366268
Purchase history
- Companies traded
- 1
- Purchases · 12M
- 3
- Purchases · 24M
- 4
- Average purchase
- $582.4K
- Median purchase
- $533.8K
- Gross purchase value
- $2.3M
Companies: Inhibrx Biosciences, Inc.
4 SEC accession(s) · 0 joint-owner event(s). Values are reported Form 4 transaction values in USD.
Qualifying purchase disclosures
| Published | Company | Ticker | Role | Reported value | SEC source |
|---|---|---|---|---|---|
| 2026-09-23 | Inhibrx Biosciences, Inc. | INBX | Director | $500.0K | Open filing |
| 2026-09-17 | Inhibrx Biosciences, Inc. | INBX | Director | $500.0K | Open filing |
| 2026-09-08 | Inhibrx Biosciences, Inc. | INBX | Director | $567.6K | Open filing |
| 2024-11-22 | Inhibrx Biosciences, Inc. | INBX | Director | $761.9K | Open filing |
Post-purchase outcomes
Excess return = stock return − S&P 500 ETF (SPY adjusted close) return. Returns start on the first shared trading session on or after publication.
| Period | Completed events | Price coverage | Hit rate | Median excess return | Average excess return | Worst excess return |
|---|---|---|---|---|---|---|
| 5D | 4Small Sample | 100.0% (4/4) | 50.0% (2/4) | -2.3% | -1.3% | -6.5% |
| 20D | 2Small Sample | 66.7% (2/3) | 50.0% (1/2) | -8.9% | -8.9% | -20.3% |
| 60D | 1Small Sample | 100.0% (1/1) | 0.0% (0/1) | -11.9% | -11.9% | -11.9% |
| 120D | 1Small Sample | 100.0% (1/1) | 0.0% (0/1) | -7.4% | -7.4% | -7.4% |
Research patterns
- First purchase in 12M
- 1/3
- Large purchase ≥ $100k
- 4/4
- Cluster buying · 15D
- 3/4
- Buying the dip
- 2/3
Routine / opportunistic: Not classifiable. These labels never affect the score or ranking.
Small samples remain visible but are not scored. This research enrichment never affects US-v1.1.